Bristol-Myers Squibb Company (NYSE:BMY) finished Thursday with an addition of $1.83 to close at $71.29, an upside of 2.63 percent. An average of 11,121,640 shares of common stock have been traded in the last five days. There was a fall of -$0.49 in the past week, and it reached a new high 34 times over the past 12 months. The last 20 days have seen an average of 11,252,455 shares traded, while the 50-day average volume stands at 9,581,424.
BMY stock has decreased by -2.03% in the last month. The company shares reached their 1-month lowest point of $65.95 on 08/30/22. With the stock rallying to its 52-week high on 06/27/22, shares of the company touched a low of $53.22 and a high of $80.59 in 52 weeks. It has reached a new high 33 times so far this year and achieved 14.34% or $8.94 in price. In spite of this, the price is down -11.54% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
3 days have passed since Bristol-Myers Squibb Company (BMY) last reported insider trading activity. Caforio Giovanni, who is Board Chair and CEO, most recently acquired $25,000 shares at $69.71 per share on Sep 20. In this transaction, the insider spent $1,742,750. Board Chair and CEO, Caforio Giovanni, disposed of 50,000 shares at a price of $71.84 on Sep 15. The insider now owns more than $3,592,000 worth of shares. Prior to that, EVP, Chief Human Resources Powell Ann went on to Sale 25,000 shares at $70.75 each on Sep 14. An amount of $1,768,750 was transacted.
Bristol-Myers Squibb Company (BMY) has a trailing price-to-earnings (P/E) ratio of 23.69. The stock’s beta is 0.41. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.24, the price-to-book (PB) ratio at 4.67, and the price-to-cash flow ratio at 15.66.
The company has a payout ratio of 67.90%. The company’s most recent quarterly dividend payment was $0.54 a share, without any change from last year. Its latest increase dividend $0.05 reported on Monday December 13 2021.
The quick ratio of Bristol-Myers Squibb Company for the three months ended June 29 was 1.30, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.14 and a total debt to equity ratio of 1.29 for the quarter ending June 29. Its gross profit as reported stood at $36.45 billion compared to revenue of $46.38 billion.
For the three-month period that ended June 29, Bristol-Myers Squibb Company had $2.48 billion in cash and short-term investments compared to $37.11 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.42 billion in the quarter, while revenues of $1.28 billion were grew 25.76%. The analyst consensus anticipated Bristol-Myers Squibb Company’s latest quarter earnings to come in at $1.79 per share, but it turned out to be $1.93, a 7.80% surprise. For the quarter, EBITDA amounted to $4.54 billion. Shareholders own equity worth $2.14 billion.
From a technical analysis perspective, let’s take a brief look at Bristol-Myers Squibb Company (BMY) price momentum. RSI 9-day as of the close on 22 September was 54.63%, suggesting the stock is Neutral, with historical volatility in this time frame at 27.80%.
As of today, BMY’s price is $70.44 -0.68% or -$0.49 from its 5-day moving average. BMY is currently trading -1.56% lower than its 20-day SMA and -5.29% lower than its 100-day SMA. However, the stock’s current price level is -4.35% below the SMA50 and +25.44% above the SMA200.
The stochastic %K and %D were 32.51% and 36.26%, respectively, and the average true range (ATR) was 1.73. With the 14-day stochastic at 40.28% and the average true range at 1.69, the RSI (14) stands at 51.13%. The stock has reached -0.71 on the 9-day MACD Oscillator while the 14-day reading was at -0.08.
Berenberg downgraded Bristol-Myers Squibb Company (NYSE: BMY) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy.